Literature DB >> 26634473

Role of survivin in the pathogenesis of papillary thyroid carcinoma.

J Y Li1, J Shi2, J F Sang1, Y Z Yao1, X C Wang1, L Su1.   

Abstract

The purpose of this study was to assess the correlation between the survivin gene and the occurrence and pathogenesis of papillary thyroid carcinoma (PTC). Sixty patients with PTC and no preoperative chemotherapy were recruited for the study and 30 thyrophyma patients receiving operative treatment in Drum Tower Hospital (Nanjing, China) were included as the control group. The protein expression levels of survivin were assessed by immunoblotting and immunohistochemical analysis of tissues from both patient groups. For survivin gene knockdown experiments, two target sequences were selected based on the mRNA sequence of survivin and two pairs of siRNA interference sequences were designed and synthesized accordingly. The siRNAs were shown to be successfully transfected into SW579 carcinoma cells and the resulting survivin knockdown was assessed by RT-PCR and immunofluorescence. Survivin was shown by immunohistochemistry to be distributed in the cytoplasm of PTC and thyrophyma cells, with the signal being significantly stronger in PTC cells than in thyrophyma cells and statistical analysis of immunostaining data further showed survivin to be more highly expressed  (P < 0.05) in the PTC tissue than in the thyrophyma tissue. Transfection of SW579 cells with siRNA was found to be effective in knocking down the expression levels of survivin: 87.3 and 76.2% knockdown was achieved with sh-Survivin-1 and sh-Survivin-2, respectively. The findings reported here show that survivin is highly expressed in PTC and may therefore play a role in the occurrence, lymph node metastasis, and clinical staging of PTC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26634473     DOI: 10.4238/2015.November.24.19

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  6 in total

Review 1.  Epigenetic mechanism of survivin dysregulation in human cancer.

Authors:  Hui Lyu; Jingcao Huang; Zhimin He; Bolin Liu
Journal:  Sci China Life Sci       Date:  2018-01-04       Impact factor: 6.038

2.  SURVIVIN POSITIVITY AND PROGNOSTIC FACTORS IN PAPILLARY THYROID CARCINOMAS.

Authors:  E Usturali Keskin; E Taştekin; N Can; A N Mut; M Celik; B Yilmaz Bulbul; F Oz Puyan; F Ozyilmaz; S Guldiken; S Ayturk; A Sezer; F Üstün
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

3.  Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles.

Authors:  Songfeng Wei; Xinwei Yun; Xianhui Ruan; Xi Wei; Xiangqian Zheng; Ming Gao
Journal:  Oncol Lett       Date:  2019-11-05       Impact factor: 2.967

Review 4.  Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers.

Authors:  Rita Niciporuka; Jurijs Nazarovs; Arturs Ozolins; Zenons Narbuts; Edvins Miklasevics; Janis Gardovskis
Journal:  Medicina (Kaunas)       Date:  2021-10-19       Impact factor: 2.948

5.  Identification of candidate genes associated with papillary thyroid carcinoma pathogenesis and progression by weighted gene co-expression network analysis.

Authors:  Xiaomin Chen; Ruoyu Wang; Tianze Xu; Yajing Zhang; Hongyan Li; Chengcheng Du; Kun Wang; Zairong Gao
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

6.  Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.

Authors:  Anna Fäldt Beding; Peter Larsson; Khalil Helou; Zakaria Einbeigi; Toshima Z Parris
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.